What the evidence says. Graded mixed: a 2001 Cochrane review and a 2024 meta-analysis (18 trials, 886 people) found the evidence for dementia/memory inadequate and inconclusive, and the large PASS stroke RCT was negative. The one consistently positive use — high-dose add-on therapy for cortical/progressive-myoclonus epilepsy — is a prescription neurology indication, not the cognitive boost it is sold for online. (Mixed evidence: Conflicting results across studies; benefit uncertain.)
What is Piracetam?
Piracetam is a nootropic used for reduces cortical myoclonus. NutriDex grades the human evidence as Mixed. Piracetam is the prototype 'nootropic,' a pyrrolidone derivative prescribed in parts of Europe and Asia but not approved by the US FDA. Despite decades of use for memory and dementia, the evidence there is weak: the 2001 Cochrane review found benefit only on a vague 'global impression of change' and none on specific cognitive measures, and a 2024 meta-analysis of 18 trials (886 patients) could not confirm any memory effect (SMD 0.75, 95% CI -0.19 to 1.69; very high heterogeneity). The large PASS trial (927 patients) showed no benefit in acute ischemic stroke. The clearest evidence is for high-dose piracetam (up to 24 g/day) as add-on therapy in cortical myoclonus and progressive myoclonus epilepsy, where randomized crossover trials show real, dose-dependent symptom relief. As a 'smart drug' for healthy adults, robust supporting data are essentially absent.
Purported Benefits
✓Reduces cortical myoclonus
✓Adjunct in progressive myoclonus epilepsy
✓Marketed for memory & cognition
✓Studied for dementia
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
Outcome
Evidence
Effect
Studies
Reduce cortical myoclonus (add-on)Randomized crossover trials show real, dose-dependent myoclonus relief at high doses; small specialized populations.
Moderate
↑ benefit · moderate
2
Improve memory / cognitionCochrane found benefit only on vague global impression; 2024 meta-analysis (18 trials) could not confirm any memory effect.
Mixed
— no effect · negligible
3
Acute ischemic stroke recovery927-patient PASS RCT showed no benefit; pooled data even hinted at slightly higher early deaths (NS).
Moderate
— no effect · negligible
2
Dosing & Compounds
Typical Dose
Cognitive trials used 2.4–8 g/day orally; myoclonus trials used up to 24 g/day. Not approved or sold as a dietary supplement in the US.
Active Compounds
Piracetam (2-oxo-1-pyrrolidine acetamide)
Safety & Cautions
⚠
Generally well tolerated; common effects are nervousness, agitation, insomnia, weight gain and GI upset. Because it lowers platelet aggregation it is contraindicated in cerebral hemorrhage and should be used cautiously with anticoagulants and antiplatelet drugs (aspirin, warfarin) and before surgery. It is renally cleared, so it is contraindicated in severe renal impairment and needs dose reduction with reduced kidney function; it is not approved as a US dietary supplement, so over-the-counter products are unregulated. Educational only — always check with your doctor or pharmacist before combining Piracetam with any medicine.
Piracetam is most often taken for Reduces cortical myoclonus, Adjunct in progressive myoclonus epilepsy, Marketed for memory & cognition, Studied for dementia. The original "nootropic" — proven for myoclonus, unproven for memory.
Does Piracetam work — what does the evidence say?
Mixed evidence. Conflicting results across studies; benefit uncertain. Piracetam is the prototype 'nootropic,' a pyrrolidone derivative prescribed in parts of Europe and Asia but not approved by the US FDA. Despite decades of use for memory and dementia, the evidence there is weak: the 2001 Cochrane review found benefit only on a vague 'global impression of change' and none on specific cognitive measures, and a 2024 meta-analysis of 18 trials (886 patients) could not confirm any memory effect (SMD 0.75, 95% CI -0.19 to 1.69; very high heterogeneity). The large PASS trial (927 patients) showed no benefit in acute ischemic stroke. The clearest evidence is for high-dose piracetam (up to 24 g/day) as add-on therapy in cortical myoclonus and progressive myoclonus epilepsy, where randomized crossover trials show real, dose-dependent symptom relief. As a 'smart drug' for healthy adults, robust supporting data are essentially absent.
What is the typical dose of Piracetam?
Cognitive trials used 2.4–8 g/day orally; myoclonus trials used up to 24 g/day. Not approved or sold as a dietary supplement in the US.
Is Piracetam safe? Any cautions or side effects?
Generally well tolerated; common effects are nervousness, agitation, insomnia, weight gain and GI upset. Because it lowers platelet aggregation it is contraindicated in cerebral hemorrhage and should be used cautiously with anticoagulants and antiplatelet drugs (aspirin, warfarin) and before surgery. It is renally cleared, so it is contraindicated in severe renal impairment and needs dose reduction with reduced kidney function; it is not approved as a US dietary supplement, so over-the-counter products are unregulated.
How many studies support Piracetam?
NutriDex cites 9 sources for Piracetam, graded "Mixed".
Cite this page
APA
Peh, D. (2026). Piracetam: Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/piracetam
BibTeX
@misc{nutridex_piracetam,
author = {Peh, Daryl},
title = {Piracetam: Benefits, Dosage, Side Effects \& Evidence},
year = {2026},
howpublished = {NutriDex --- The Supplement Research Compendium},
url = {https://nutridex.info/s/piracetam},
note = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}
For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.